Research
Hormonal
Tirzepatide is the first pharmacologic therapy approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, significantly reducing the Apnea-Hypopnea Index (AHI).
Tirzepatide (Zepbound) is now approved for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. It significantly reduces the number of breathing interruptions per hour (AHI) by 50-60%. This may lead to less daytime sleepiness and potentially reduced reliance on CPAP machines, though long-term data is still emerging.
GoodSupportsHIGH confidence
In December 2024, the FDA approved tirzepatide (Zepbound) as the first pharmacologic therapy for moderate-to-severe OSA in adults with obesity... After 52 weeks, patients taking tirzepatide (10 mg or 15 mg) had approximately 20–24 fewer apnea/hypopnea events per hour than at baseline... amounted to a 50–60% reduction in AHI with tirzepatide versus minimal change with placebo
Why this rating
Based on SURMOUNT-OSA Phase 3 RCT.
Source
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Mrudula Thiriveedi et al. · Annals of Medicine and Surgery · 2025
DOI 10.1097/ms9.0000000000004055
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (5-15 mg once weekly) significantly reduces HbA1c (by 1.5-2.5%) and body weight (by 15-25%) in patients with type 2 diabetes and obesity, outperforming standard therapies like semaglutide and insulin.Strong
- Tirzepatide improves cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, reducing heart failure hospitalizations and improving quality of life.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →